Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies

Biomaterials

Volumn 34, Issue 20, 2013, Pages 4831-4838

  Hillaireau, Hervé ^a,b   Dereuddre Bosquet, Nathalie ^c   Skanji, Rym ^a,b   Bekkara Aounallah, Fawzia ^a,b,d   Caron, Joachim ^a,b   Lepêtre, Sinda ^a,b   Argote, Sébastien ^e   Bauduin, Laurent ^f   Yousfi, Rahima ^c   Rogez Kreuz, Christine ^c   Desmaële, Didier ^a,b   Rousseau, Bernard ^e   Gref, Ruxandra ^a,b   Andrieux, Karine ^a,b   Clayette, Pascal ^c   Couvreur, Patrick ^a,b  

^a UNIV PARIS SUD   (France)

^b CNRS   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d UNIVERSITY OF SIDI BEL ABBES   (Algeria)

^e CEA SACLAY   (France)

^f DIF   (France)

Author keywords

Didanosine; Nanoassemblies; Prodrug; Squalenoylation; Zalcitabine

Indexed keywords

DIDANOSINE; NANO-ASSEMBLIES; PRODRUGS; SQUALENOYLATION; ZALCITABINE;

BIOCHEMISTRY; BIOMOLECULES; VIRUSES;

ENZYME INHIBITION;

PRODRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; PRIORITY JOURNAL; RADIOACTIVITY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; LIGHT; NANOPARTICLES; NUCLEOSIDES; PARTICLE SIZE; PRODRUGS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; SCATTERING, RADIATION; SQUALENE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TRITIUM; ZALCITABINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 84876092008     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.022     Document Type: Article

References (17)

1. Sosnik A., Chiappetta D.A., Carcaboso A.M. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. JControl Release 2009, 138(1):2-15.
2. Gallois-Montbrun S., Veron M., Deville-Bonne D. Antiviral nucleoside analogs phosphorylation by nucleoside diphosphate kinase. Mini Rev Med Chem 2004, 4(4):361-369.
3. Calogeropoulou T., Detsi A., Lekkas E., Koufaki M. Strategies in the design of prodrugs of anti-HIV agents. Curr Top Med Chem 2003, 3(13):1467-1495.
4. Skanji R., Andrieux K., Lalanne M., Caron J., Bourgaux C., Degrouard J., et al. Anew nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. Int J Pharm 2011, 414(1-2):285-297.
5. Hillaireau H., Le Doan T., Couvreur P. Polymer-based nanoparticles for the delivery of nucleoside analogues. JNanosci Nanotechno 2006, 6(9-10):2608-2617.
6. Neves das J., Amiji M.M., Bahia M.F., Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 2010, 62(4-5):458-477.
7. Couvreur P., Stella B., Reddy L.H., Hillaireau H., Dubernet C., Desmaele D., et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006, 6(11):2544-2548.
8. Reddy L.H., Marque P.-E., Dubernet C., Mouelhi S.-L., Desmaele D., Couvreur P. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. JPharmacol Exp Ther 2008, 325(2):484-490.
9. Réjiba S, Reddy LH, Bigand C, Parmentier C, Couvreur P, Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 201.;7(6):841-849.
10. Bekkara-Aounallah F., Gref R., Othman M., Reddy L.H., Pili B., Allain V., et al. Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues. Adv Funct Mater 2008, 18(22):3715-3725.
11. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220(4599):868-871.
12. Roisin A., Robin J.-P., Dereuddre-Bosquet N., Vitte A.-L., Dormont D., Clayette P., et al. Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev. JBiol Chem. 2004, 279(10):9208-9214.
13. Mabondzo A., Lenaour R., Raoul H., Clayette P., Lafuma C., Barré-Sinoussi F., et al. Invitro infection of macrophages by HIV - correlation with cellular activation, synthesis of tumor-necrosis-factor-alpha and proteolytic activity. Res Virol 1991, 142:205-212.
14. Becher F., Pruvost A., Gale J., Couerbe P., Goujard C., Boutet V., et al. Astrategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. JMass Spectrom 2003, 38(8):879-890.
15. Ojewole E., Mackraj I., Naidoo P., Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008, 70(3):697-710.
16. Lyseng-Williamson K.A., Reynolds N.A., Plosker G.L. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005, 65(3):413-432.
17. Bildstein L., Dubernet C., Marsaud V., Chacun H., Nicolas V., Gueutin C., et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. JControl Release 2010, 147(2):163-170.